Alvin Lo

$RHY Quarterly Activities Report for the 31 December 2022 period. #bowelcancer #cancer #biotech #screening #CRC #diagnostics #bloodtest #ESG #colorectalcancer #ASX #invest Link to Report: bit.ly/3JooXT1

Video Replay: $RHY MD/CEO, Glenn Gilbert, presentation to investors at @Bell_Potter Healthcare Conference 9 Nov 2022. Link to full video: bit.ly/40gwI3p #bowelcancer #cancer #diagnostics #bloodtest #CRC #ESG #colorectalcancer #invest

Video Replay: $RHY MD/CEO, Glenn Gilbert, presentation to institutional investors at MST Access Diagnostics Forum - 6 December, 2022. Link to full video: bit.ly/3uUHk9L #bowelcancer #cancer #diagnostics #bloodtest #CRC #ESG #colorectalcancer #invest

$RHY confirms ColoSTAT® is now authorised for sale in New Zealand. The Company is progressing commercial activities with the aim of quickly making ColoSTAT® available for use. #cancer #diagnostics #bloodtest #NZ #CRC #ASX #invest Link to announcement: bit.ly/3U2n7ts

@The_VIIN @rhea_longley @LindaReiling @melanie_neeland @MicrobioElla @StephenScally @GabrielaKhoury Amazing organisation! Lot of hard work I can imagine.

Congratulations!👏 @rhea_longley @LindaReiling @melanie_neeland @MicrobioElla @StephenScally @GabrielaKhoury Joyanta Modak San Lim. #VIINcareers

The team has done a fantastic job on organising such an engaging event! Make sure you say hi! A special thanks to Rebecca Smith @The_VIIN program manager for supporting the committee #VIINcareers

What a wonderful evening hearing about the diverse career paths of @CatrionaNR @alvinlo80 @melanie_neeland, @v_j_j_j and Victoria Jameson. There are many different opportunities out there for people who have STEM training. @GabrielaKhoury signing out at #VIINcareers

$RHY completes initial biomarker review to support platform expansion of its core cancer detection technology into other target cancers: ▶️Breast ▶️Lung ▶️Cervical ▶️Pancreatic and ▶️Gastric. #cancer #diagnostics #ESG #ESGwatch #invest Link to Release: bit.ly/3B1xlDU

$RHY completes final TGA submission step filing for an Australian Register of Therapeutic Goods (ARTG) listing to enable the sale of ColoSTAT® for clinical use in Australia. #bowelcancer #cancer #diagnostics #ESG #colorectalcancer #invest Link to Release: bit.ly/3w6YQcu

$RHY confirms ColoSTAT® clinical trial (Study 7) has successfully achieved and met primary endpoint. ☑️ 81% Sensitivity / Specificity of 91% ☑️ 35% more accurate than market standard FIT #cancer #diagnostics #bloodtest #ESG #invest Link to announcement: bit.ly/3LF8uYI

#RHY is pleased to advise that it will be an addition to the All Ordinaries Index (XAO), effective 21 March, 2022. The Index represents the 500 largest companies in the Australian equities market and is rebalanced annually in March. Link to Announcement: bit.ly/3IHIFGh

In the Dec21 quarter, $RHY continued to demonstrate a strong pathway toward the commercialisation of ColoSTAT® this year. #bowelcancer #cancer #diagnostics #bloodtest #ESG #CRC #colorectalcancer #ASX #invest Link to Report: bit.ly/3rX9aQG

$RHY raises $6.53M in an exclusive Placement to a single, global institutional funds manager to accelerate commercial activities for ColoSTAT®. #cancer #diagnostics #bloodtest #ESG #CRC #ASX #invest Link to announcement: bit.ly/3ETuxXD

$RHY targets 5 additional cancer diagnostic markets as part of its platform technology expansion, confirming a development program has commenced to validate commercial pathways. #cancer #diagnostics #bloodtest #ESG #CRC #ASX #invest Link to announcement: bit.ly/3oQOOII

We published a research update on @rhythmbiosc (ASX:RHY, SP $1.49): Ticket to Europe booked. We have increased our valuation to $4.19 per share. Read the full report here: lnkd.in/e7xYJQmh #PSR #RhythmBioSciences

$RHY confirms CE Mark has been granted for ColoSTAT®, enabling access to an addressable European market of 231 million people, valued at ~US$12 billion. #CEMark #colorectalcancer #bowelcancer #cancer #bloodtest #ESG #CRC #ASX #invest Link to announcement: bit.ly/3xAFjA8

Testing of $RHY commercially manufactured ColoSTAT® test-kits continues to confirm high accuracy, significantly outperforming current market standard test. #colorectalcancer #bowelcancer #cancer #bloodtest #CRC #ESG #ASXnews #invest Link to announcement: bit.ly/3vtMaKK

$RHY receives $2.4M R&D tax incentive following increased activities undertaken by Rhythm during FY21, advancing its cancer diagnostics technology. #colorectalcancer #bowelcancer #cancer #bloodtest #CRC #ASX #ESG #ASXnews #invest Link to announcement: bit.ly/3Bd4uJZ

$RHY confirms a key milestone reached with the successful completion of the extensive patient recruitment phase for its ColoSTAT® clinical trial (Study 7). #colorectalcancer #bowelcancer #cancer #crc #ASX #ESG #ASXnews #invest Link to announcement: bit.ly/3u7XWtC

$RHY achieves an important milestone with completion of the first of two steps toward TGA approval receiving formal acceptance of its Manufacturers Evidence documentation. #colorectalcancer #bowelcancer #cancer #crc #ASXnews #invest Link to announcement: bit.ly/2XfANsG

$RHY completes a strongly oversubscribed Rights Issue, adding a Placement to sophisticated and other exempt investors increasing the amount raised to $5.58M (less costs). #colorectalcancer #bowelcancer #cancer #crc #asxnews #invest Link to announcement: bit.ly/3zTTD7k